✦ LIBER ✦

Metabolic disorders and mental retardation

✍ Scribed by Kahler, Stephen G. ;Fahey, Michael C.

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 139 KB
Volume: 117C
Category: Article
ISSN: 0148-7299
DOI: 10.1002/ajmg.c.10018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Measuring behavior in genetic disorders

Measuring behavior in genetic disorders of mental retardation

✍ Hodapp, Robert M. ;Dykens, Elisabeth M. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

## Abstract As researchers have examined the so‐called “behavioral phenotypes” of different genetic mental retardation conditions, the measurement of behavior becomes increasingly important. From earlier, more global examinations of noteworthy behaviors or profiles, recent researchers have moved fr

Overview: Progressive neurological disor

Overview: Progressive neurological disorders in mental retardation and developmental disabilities

✍ Lott, Ira T. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Mental retardation and seizure disorder

Mental retardation and seizure disorder in Schimke immunoosseous dysplasia

✍ Sigurdardottir, Solveig; Myers, Scott M.; Woodworth, James M.; Raymond, Gerald V 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 16 KB 👁 2 views

Schimke immunoosseous dysplasia (SID) is a rare, pleiotropic disorder compromising spondyloepiphyseal dysplasia, nephrotic syndrome, defective T-cell-mediated immunity, and vascular changes which can lead to cerebral infarcts. The cause is unknown but an autosomal recessive inheritance pattern has b

Mental retardation and osteosclerosis

✍ Hunter, Alasdair G. W. ;Macpherson, Roderick I. ;Opitz, John M. 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB 👁 2 views

Psychopharmacology of mood disorders in

Psychopharmacology of mood disorders in persons with mental retardation and autism

✍ Hellings, Jessica A. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views

The ever-growing range of designer drugs such as selective serotonin reuptake inhibitors (SSRIs) and other new antidepressants, atypical antipsychotic agents, and antiseizure medications may improve treatment efficacy and safety for persons with mood disorders and mental retardation (MR) and autism.

FBN1, TGFBR1, and the Marfan-craniosynos

FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited

✍ L.C. Adès; K. Sullivan; A. Biggin; E.A. Haan; M. Brett; K.J. Holman; J. Dixon; S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

## Abstract The recent identification of __TGFBR2__ mutations in Marfan syndrome II (MFSII) [Mizuguchi et al. (2004); Nat Genet 36:855–860] and of __TGFBR1__ and __TGFBR2__ mutations in Loeys–Dietz aortic aneurysm syndrome (LDS) [Loeys et al. (2005); Nat Genet 37:275–281] [OMIM 609192] has provided